Revenue for the quarter ended March 31 was $279 million, up from $251 million a year ago.
Analysts' estimates for the quarter were not readily available for comparison.
Insider Sell: Block |
Insider Sell: Berkshire Hathaway |
Insider Sell: Trupanion |
Insider Buy: Ikena Oncology |
Insider Sell: Apellis Pharmaceuticals |